<DOC>
	<DOCNO>NCT00079612</DOCNO>
	<brief_summary>The purpose study : - Find BAY 43-9006 prevents growth tumor - For patient stable cancer status 3 month treatment safer and/or effective continue give BAY 43-9006 stop give BAY 43-9006 time . - Find long effect BAY 43-9006 tumor . To assess safety BAY 43-9006 ( sorafenib ) treatment advanced refractory cancer . - Measure amount BAY 43-9006 target blood stream patient .</brief_summary>
	<brief_title>Study Nexavar ( Sorafenib , BAY 43-9006 ) Patients With Advanced Refractory Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; 18 year Patients refractory solid cancer curative palliative measure fail patient whose treatment consider ineffective intolerable Patients noncolorectal cancer eligible must progress time screen assessment treatment exist Patients least one ( 1 ) measurable tumor , per WHO Tumor Response Criteria Histological cytological documentation cancer ECOG Performance status 0 1 Life expectancy least 12 week Adequate bone marrow , liver renal function ( assess follow laboratory requirement ) : Hemoglobin &gt; /= 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; /=1,500/mm3 Platelet count = 100,000/Âµl3 Total bilirubin &lt; /=1.0 time upper limit normal unless due Gilbert 's ALT AST &lt; /= 2.5 x upper limit normal . ( For patient hepatic involvement cancer , ALT AST &lt; 5.0 x upper limit normal ) PTINR/PTT &lt; 1.5 x upper limit normal . ( Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . In addition , patient must monitor weekly coagulation assessment throughout Runin Period ) Serum creatinine &lt; 1.5 x upper limit normal Patients meet follow criterion time screen exclude : Non small cell lung cancer , hepatocellular cancer , CML AML Serious cardiac arrhythmia Congestive Heart Failure ( NYHA Class 3 4 ) Active coronary artery disease ischemia Active acute infection could worsen anticancer therapy interfere study Known HIV infection Metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry Patients currently receive medication ( steroid anticonvulsant therapy ) seizure disorder History organ allograft Previous concurrent cancer distinct cancer evaluate study . Several situation exclude , include cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor cancer definitively treat great 3 year Anticancer chemotherapy immunotherapy study within 4 week prior first dose study drug Radiotherapy study within 3 week prior first dose study drug Bone marrow transplant stem cell rescue within 4 month prior first dose study drug Biological response modifier , GCSF within 3 week prior study entry Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study study Investigational drug therapy outside trial within 4 week prior screen assessment Any previous exposure Ras pathway inhibitor Pregnant breast feeding patient . Women child bear potential must negative pregnancy test . Adequate barrier contraception require male female patient entire course trial Substance abuse , medical psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient and/or compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>RCC</keyword>
	<keyword>Cancer</keyword>
</DOC>